Literature DB >> 34587561

Divergent functions of IL-17-family cytokines in DSS colitis: Insights from a naturally-occurring human mutation in IL-17F.

Chunsheng Zhou1, Dongwen Wu2, Chetan Jawale1, Yang Li1, Partha S Biswas1, Mandy J McGeachy1, Sarah L Gaffen3.   

Abstract

The IL-17 family is structurally distinct from other cytokine subclasses. IL-17A and IL-17F, the most closely related of this family, form homodimers and an IL-17AF heterodimer. While IL-17A and IL-17F exhibit similar activities in many settings, in others their functions are divergent. To better understand the function of IL-17F in vivo, we created mice harboring a mutation in Il17f originally described in humans with unexplained chronic mucosal candidiasis (Ser-65-Leu). We evaluated Il17fS65L/S65L mice in DSS-colitis, as this is one of the few settings where IL-17A and IL-17F exhibit opposing activities. Specifically, IL-17A is protective of the gut epithelium, a finding that was revealed when trials of anti-IL-17A biologics in Crohn's disease failed and recapitulated in many mouse models of colitis. In contrast, mice lacking IL-17F are resistant to DSS-colitis, partly attributable to alterations in intestinal microbiota that mobilize Tregs. Here we report that Il17fS65L/S65L mice do not phenocopy Il17f-/- mice in DSS colitis, but rather exhibited a worsening disease phenotype much like Il17a-/- mice. Gut inflammation in Il17fS65L/S65L mice correlated with reduced Treg accumulation and lowered intestinal levels of Clostridium cluster XIV. Unexpectedly, the protective DSS-colitis phenotype in Il17f-/- mice could be reversed upon co-housing with Il17fS65L/S65L mice, also correlating with Clostridium cluster XIV levels in gut. Thus, the Il17fS65L/S65L phenotype resembles an IL-17A deficiency more closely than IL-17F deficiency in the setting of DSS colitis.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34587561      PMCID: PMC8627693          DOI: 10.1016/j.cyto.2021.155715

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  46 in total

Review 1.  Secukinumab: first global approval.

Authors:  Mark Sanford; Kate McKeage
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

Review 2.  Functional specialization of interleukin-17 family members.

Authors:  Yoichiro Iwakura; Harumichi Ishigame; Shinobu Saijo; Susumu Nakae
Journal:  Immunity       Date:  2011-02-25       Impact factor: 31.745

Review 3.  IL-17-Mediated Immunity to the Opportunistic Fungal Pathogen Candida albicans.

Authors:  Heather R Conti; Sarah L Gaffen
Journal:  J Immunol       Date:  2015-08-01       Impact factor: 5.422

4.  Antibody blockade of IL-17 family cytokines in immunity to acute murine oral mucosal candidiasis.

Authors:  Natasha Whibley; Elaine Tritto; Elisabetta Traggiai; Frank Kolbinger; Pierre Moulin; Dominique Brees; Bianca M Coleman; Anna J Mamo; Abhishek V Garg; Jillian R Jaycox; Ulrich Siebenlist; Michael Kammüller; Sarah L Gaffen
Journal:  J Leukoc Biol       Date:  2016-01-04       Impact factor: 4.962

5.  Crystal structures of interleukin 17A and its complex with IL-17 receptor A.

Authors:  Shenping Liu; Xi Song; Boris A Chrunyk; Suman Shanker; Lise R Hoth; Eric S Marr; Matthew C Griffor
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 6.  Mucocutaneous IL-17 immunity in mice and humans: host defense vs. excessive inflammation.

Authors:  J Li; J-L Casanova; A Puel
Journal:  Mucosal Immunol       Date:  2017-11-29       Impact factor: 7.313

7.  IL-12- and IL-23-induced T helper cell subsets: birds of the same feather flock together.

Authors:  Estelle Bettelli; Vijay K Kuchroo
Journal:  J Exp Med       Date:  2005-01-17       Impact factor: 14.307

8.  Cutting edge: IL-17-secreting innate lymphoid cells are essential for host defense against fungal infection.

Authors:  André Gladiator; Nicolette Wangler; Kerstin Trautwein-Weidner; Salomé LeibundGut-Landmann
Journal:  J Immunol       Date:  2012-12-19       Impact factor: 5.422

9.  Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.

Authors:  Iain B McInnes; Philip J Mease; Christopher T Ritchlin; Proton Rahman; Alice B Gottlieb; Bruce Kirkham; Radhika Kajekar; Eumorphia-Maria Delicha; Luminita Pricop; Shephard Mpofu
Journal:  Rheumatology (Oxford)       Date:  2017-11-01       Impact factor: 7.580

10.  Role of innate lymphoid cells in chronic colitis during anti-IL-17A therapy.

Authors:  Chan Hyuk Park; A-Reum Lee; Sang Bong Ahn; Chang Soo Eun; Dong Soo Han
Journal:  Sci Rep       Date:  2020-01-15       Impact factor: 4.379

View more
  1 in total

1.  Mucosal fungi promote gut barrier function and social behavior via Type 17 immunity.

Authors:  Irina Leonardi; Iris H Gao; Woan-Yu Lin; Megan Allen; Xin V Li; William D Fiers; Meghan Bialt De Celie; Gregory G Putzel; Rhonda K Yantiss; Melanie Johncilla; Dilek Colak; Iliyan D Iliev
Journal:  Cell       Date:  2022-02-16       Impact factor: 41.582

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.